EUVIMEDEUVIMED entdecken
Leitlinie

L26/O-065 Genetics of POI: a leap for diagnosis and personalized medicine in new guidelines

M. Misrahi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.065 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M. Misrahi.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary ovarian insufficiency (POI) affects 1- 3.7% of women under 40 years and represents a major cause of infertility and long-term morbidity. Historically considered a clinically heterogeneous and frequently idiopathic condition (∼70% of cases), POI has long remained poorly understood. Chromosomal abnormalities are identified in ∼10-13% of patients, mainly involving the X chromosome. Until recently, a single gene FMR1, was studied for unexplained POI in most centers, positive in 3-5% of cases. Over the past decade, advances in genetics, particularly through next-generation sequencing (NGS), has allowed to identify a large number of genes causing POI. We have studied the largest international cohort of patients with unexplained POI using a custom-made NGS-POI panel comprising all known genes involved. We have shown that a genetic diagnosis can be established in 29,3% of patients. This high yield allows to support a routine genetic diagnosis in unexplained POI. We have shown a structured genetic architecture in POI. Three major functional pathways account for more than 90% of cases: genes involved in meiosis and DNA repair (37.4%), follicular growth (35.4%), metabolism and mitochondrial functions (19%). These pathways correspond to distinct biological mechanisms and are associated with different clinical phenotypes, Overall, POI should no longer be viewed as a single entity but as a spectrum of genetically defined conditions. Defects in meiosis and DNA repair genes represent the leading group and primarily affect the establishment of ovarian reserve during fetal life. These alterations impair meiotic progression and genome integrity, leading to early oocyte apoptosis and severe depletion of the follicular pool. Importantly, many of these genes are also involved in cancer susceptibility pathways, establishing a direct link between reproductive lifespan, genome stability, and tumor development. This provides a unique opportunity for early identification of at-risk patients and implementation of preventive strategies, including long-term surveillance and adapted clinical management. In contrast, alterations in other genes are more often associated with impaired follicular activation, maturation, or survival, rather than early depletion of the ovarian reserve. In these patients, a dormant follicular pool may persist despite overt ovarian dysfunction. This distinction has major clinical implications, as it identifies a subgroup of patients in whom fertility preservation strategies may be effective if implemented early, ideally at or shortly after diagnosis before accelerated follicular atresia occurs. Conventional biomarkers such as AMH do not reliably reflect the status of the primordial follicle pool, underscoring the critical role of genetic diagnosis in this context. Importantly, genetic analysis also enables reclassification of apparently isolated POI into syndromic forms, revealing associated metabolic, neurological, cardiological signs or other systemic conditions that may require multidisciplinary management. Beyond diagnosis, genetic stratification has direct implications for clinical care. It guides individualized counseling, allows prevention strategies when cancer predisposing genes are identified and supports early fertility preservation strategies, including ovarian tissue cryopreservation, in patients with predicted residual ovarian reserve. It also facilitates family screening, allowing early identification of at-risk relatives and anticipatory management. The integration of genetic diagnosis into routine clinical practice in the novel ESHRE, ASRM, CREWHIRL, and IMS guidelines represents a major step improving personalized care. Genetic testing is increasingly recognized as a key tool not only for etiological diagnosis but also for risk stratification, fertility counseling, and long-term management. Overall, these advances position POI as a model of precision medicine in reproductive endocrinology. By linking specific molecular defects to distinct pathophysiological mechanisms, genetics paves the way for the development of innovative targeted therapies in the near future. Emerging strategies, such as in vitro activation of dormant follicles, modulation of the ovarian microenvironment, and metabolic interventions, illustrate the potential for mechanism-based treatments aimed at restoring ovarian function.

Zitieren

APA

Misrahi, M. (2026). L26/O-065 Genetics of POI: a leap for diagnosis and personalized medicine in new guidelines. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.065

Vancouver

Misrahi M. L26/O-065 Genetics of POI: a leap for diagnosis and personalized medicine in new guidelines. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.065

BibTeX
@article{Misrahi2026,
  author = {Misrahi, M.},
  title = {L26/O-065 Genetics of POI: a leap for diagnosis and personalized medicine in new guidelines},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.065}
}
Kostenlos starten →